Diagnostics In Brief
This article was originally published in The Gray Sheet
Executive Summary
Ortho Clinical Diagnostics assays: J&J subsidiary announces FDA approval of two new infectious disease assays to run on its recently launched Vitros 5600 and 3600 immunodiagnostic systems July 21 at the American Association for Clinical Chemistry annual meeting in Chicago. The new Vitros Anti-HCV immunoassay is used to confirm hepatitis C diagnosis by qualitatively detecting immunoglobulin G antibodies to hepatitis C in human serum and plasma. The second assay, Vitros Anti-HBc IgM, detects hepatitis B. The assays are the first of six infectious disease assays the firm plans to launch on the 5600 and 3600 systems beginning in 2010, Ortho Clinical Diagnostics VP-Worldwide Marketing Betsy Hanna says. Three tests are pending FDA approval, and the final test, a hepatitis B surface antibody assay, will be submitted for FDA approval at the end of the summer, Hanna said
You may also be interested in...
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.
GLP-1 Coverage Restrictions In Medicare Part D Surge As Demand For Obesity Drugs Grows
A major shift from unfettered coverage to prior authorizations was recorded by MMIT over the past year for the leading GLP-1/GIP agonist diabetes drugs. Public interest in using the drugs off label for weight loss drove the change.
Roche Gets Adjuvant ALK+ Lung Cancer To Itself With Alecensa Approval
The US FDA cleared Roche’s supplemental approval request for ALK inhibitor Alecensa in ALK-positive non-small cell lung cancer following tumor resection.